BOLD-100 is under clinical development by Bold Therapeutics and currently in Phase II for Gastrointestinal Tumor. According to GlobalData, Phase II drugs for Gastrointestinal Tumor does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BOLD-100 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BOLD-100 overview

BOLD-100 (IT-139, NKP-1339) is under development for the treatment of solid tumors including pancreatic cancer, gastroesophageal (GE) junction carcinomas, gastric cancer, lung cancer, colon cancer, gastrointestinal tumor, treatment-resistant metastatic colorectal cancer (mCRC), bile duct cancer, pancreatic cancer, pancreatic ductal adenocarcinoma,triple-negative breast cancer, sarcomas, bladder cancer, multiple myeloma, esophageal squamous cell carcinoma (ESCC) and coronavirus disease (COVID-19). It is sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)]. The drug candidate is administered through intravenous route. It targets GRP78. It was also under development for the treatment of neuroendocrine tumors, non-small cell lung cancer, breast cancer, esophageal cancer, osteosarcoma, metastatic melanoma and liver cancer. It acts as PD-1 inhibitor.

Bold Therapeutics overview

Bold Therapeutics is a clinical-stage biotechnology company developing cancer therapy for the treatment of gastric, pancreatic, colorectal, and other cancers in combination with existing anti-cancer therapies. The company is headquartered in Vancouver, British Columbia.

For a complete picture of BOLD-100’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.